Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients.

Springerplus · 2015 · PMC4402684 · PMID 25918681

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

nearly significantp = 0.051so close (0.05 < p ≤ 0.1)

As concerned sEGFR, a cut-off value of 56.87 ng/mL clearly differentiated among patients expressing lower levels and experiencing lower median overall survival periods of 4.2 months in contrast to patients displaying levels well above of the cut-off value who presented median overall survival intervals of 9.5 months ( p = 0.016); progression-free survival differences were nearly significant ( p = 0.051).

also in 3,349 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.